Clinical Trial Update: Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluating induction therapy combining an intercalated tyrosine kinase inhibitor with chemotherapy for NSCLC patients with activating…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA | Phase 2, Phase 3 | Status: TERMINATED